phgenomicsФармакогенетика и фармакогеномикаPharmacogenetics and Pharmacogenomics2588-05272686-8849LLC "Izdatelstvo OKI"10.37489/2588-0527-2025-4-10-17FYBPPDphgenomics-342Research ArticleФАРМАКОТРАНСКРИПТОМИКАPHARMACOTRANSCRIPTOMICSПерспективы фармакотранскриптомики в понимании эффектов противоэпилептических препаратов и поиске новых классов противоэпилептических препаратовProspects of pharmacotranscriptomics in understanding the effects of antiepileptic drugs and searching for new classes of antiepileptic drugshttps://orcid.org/0000-0002-2840-837XШнайдерН. А.ShnayderN. A.

Шнайдер Наталья Алексеевна — д. м. н., профессор, главный научный сотрудник Института персонализированной психиатрии и неврологии; ведущий научный сотрудник центра коллективного пользования «Молекулярные и клеточные технологии»

Natalia A. Shnayder — Dr. Sci. (Med.), Professor, Chief Researcher of the Institute of Personalized Psychiatry and Neurology; Leading Researcher of the Centre for Collective Use "Molecular and Cellular Technologies"

naschnaider@yandex.ruhttps://orcid.org/0000-0001-8279-4198БадерВ. В.BaderV. V.

Бадер Виолетта Владимировна — младший научный сотрудник Института персонализированной психиатрии и неврологии; врач-невролог городского эпилептологического центра

Violetta V. Bader — Yunior Researcher of the Institute of Personalized Psychiatry and Neurology neurologist, City Epileptology Centre

grechkina.vv@mail.ruhttps://orcid.org/0000-0003-1874-9434НасыроваР. Ф.NasyrovaR. F.

Насырова Регина Фаритовна — д. м. н., главный научный сотрудник, руководитель Института персонализированной психиатрии и неврологии; профессор кафедры психиатрии, общей и клинической психологии

Regina F. Nasyrova — Dr. Sci. (Med.), Chief Scientific Officer, Head of the Institute of Personalized Psychiatry and Neurology; Professor, Department of Psychiatry, General and Clinical Psychology

regina_nmrcpn@mail.ruФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева»; ФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого»РоссияBekhterev National Medical Research Centre for Psychiatry and Neurology; Voino-Yasenetsky Krasnoyarsk State Medical UniversityRussian FederationФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева»; СПбГКУЗ «Городская психиатрическая больница № 6 (стационар с диспансером)»РоссияBekhterev National Medical Research Centre for Psychiatry and Neurology; City Psychiatric Hospital No. 6 (hospital with dispensary)Russian FederationФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева»; ФГБОУ ВО «Тульский государственный университет»РоссияBekhterev National Medical Research Centre for Psychiatry and Neurology»; Tula State UniversityRussian Federation202525122025041017Copyright © Шнайдер Н.А., Бадер В.В., Насырова Р.Ф., 20262026Шнайдер Н.А., Бадер В.В., Насырова Р.Ф.Shnayder N.A., Bader V.V., Nasyrova R.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/342

Фармакотранскриптомика — это один из важных «пазлов» мультиомического подхода к оценке эффективности и безопасности лекарственных средств (ЛС), наряду с фармакометаболомикой и фармакогеномикой. Фармакотранскриптомика помогает понять, как изменяется экспрессия генов (транскриптом) пациента в ответ на воздействие ЛС (дозу, длительность приёма, и т. д.), особенно при их длительном приёме. Этим объясняется интерес исследователей к фармакотранскриптомике противоэпилептических препаратов (ПЭП), поскольку до 60-70 % людей, страдающих эпилепсией, получают ПЭП пожизненно. С одной стороны, этот «пазл» фармакомультиомики может помочь понять механизмы действия ПЭП, предсказать реакцию на них и определить потенциальные лекарственные мишени или биомаркеры (например, микроРНК). С другой стороны, несомненны перспективы фармакотранскриптомики в поиске потенциально новых классов ПЭП

Pharmacotranscriptomics is one of the important components of the multiomics approach to evaluating the efficacy and safety of drugs, along with pharmacometabolomics and pharmacogenomics. Pharmacotranscriptomics helps to understand how a patient's gene expression (transcriptome) changes in response to drug exposure (dose, duration of administration, etc.), especially during long-term use. This explains the researchers' interest in the pharmacotranscriptomics of antiepileptic drugs (AEDs), since lifelong AED therapy is required for up to 60-70% of people with epilepsy. This component of pharmacomultiomics can help in understanding the mechanisms of action of antiepileptic drugs, predicting treatment response, and identifying potential drug targets or biomarkers (for example, microRNAs). On the other hand, the prospects of pharmacotranscriptomics in the search for potentially new classes of AEDs are undeniable.

персонализированная неврологиямультиомикатранскриптомикафармакотранскриптомикапротивоэпилептические препаратыэффективностьбезопасностьбиомаркерымикроРНКpersonalized neurologymultiomicstranscriptomicspharmacotranscriptomicsantiepileptic drugsefficacysafetybiomarkersmicroRNAsReferencesКарлов В.А. Эпилепсия у детей и взрослых женщин и мужчин : Руководство для врачей. 2-е издание. БИНОМ. 2019; 896 с. ISBN 978 5-6042641-0-2. [Karlov V.A. Epilepsy in children and adult women and men: A guide for doctors. 2nd edition. BINOM. 2019; 896 p. ISBN 978-5-6042641 0-2 (In Russ.)].Карлов В.А. Эпилепсия у детей и взрослых женщин и мужчин : Руководство для врачей. 2-е издание. БИНОМ. 2019; 896 с. ISBN 978 5-6042641-0-2. [Karlov V.A. Epilepsy in children and adult women and men: A guide for doctors. 2nd edition. BINOM. 2019; 896 p. ISBN 978-5-6042641 0-2 (In Russ.)].Бочанова Е.Н., Дмитренко Д.В., Егорова А.Т. [и др.]. Эпилепсия и беременность. 2-е издание, переработанное и дополненное. ГЭОТАР-Медиа. 2022;296 с. [Bochanova E.N., Dmitrenko D.V., Egorova A.T. et al. Epilepsy and pregnancy. 2nd edition, revised and supplemented. GEOTAR-Media. 2022; 296 p. (In Russ.)].Бочанова Е.Н., Дмитренко Д.В., Егорова А.Т. [и др.]. Эпилепсия и беременность. 2-е издание, переработанное и дополненное. ГЭОТАР-Медиа. 2022;296 с. [Bochanova E.N., Dmitrenko D.V., Egorova A.T. et al. Epilepsy and pregnancy. 2nd edition, revised and supplemented. GEOTAR-Media. 2022; 296 p. (In Russ.)].Rubio C, Gatica F, Uribe E, et al. Molecular and Genetic Mechanisms of Neurotoxicity During Anti-seizure Medications Use. Rev de Investig Clínica. 2023;75(1):1–12. doi:10.24875/RIC.22000260Rubio C, Gatica F, Uribe E, et al. Molecular and Genetic Mechanisms of Neurotoxicity During Anti-seizure Medications Use. Rev de Investig Clínica. 2023;75(1):1–12. doi:10.24875/RIC.22000260Zhuravlev NM, Shnayder NA, Vaiman EE, et al. Interindividual Variability of Anticonvulsant-Induced QT Prolongation Risk. Pers Psychiatry Neurol. 2022;2(1):22-45. doi:10.52667/2712-9179-2022-2-1-23-45Zhuravlev NM, Shnayder NA, Vaiman EE, et al. Interindividual Variability of Anticonvulsant-Induced QT Prolongation Risk. Pers Psychiatry Neurol. 2022;2(1):22-45. doi:10.52667/2712-9179-2022-2-1-23-45Shnayder NA, Pekarets NA, Pekarets NI, et al. MicroRNAs as Epigenetic Biomarkers of Pathogenetic Mechanisms of the Metabolic Syndrome Induced by Antiseizure Medications: Systematic Review. J Clin Med. 2025;14(7):2432. doi:10.3390/jcm14072432Shnayder NA, Pekarets NA, Pekarets NI, et al. MicroRNAs as Epigenetic Biomarkers of Pathogenetic Mechanisms of the Metabolic Syndrome Induced by Antiseizure Medications: Systematic Review. J Clin Med. 2025;14(7):2432. doi:10.3390/jcm14072432Шнайдер Н.А., Пекарец Н.А., Пекарец Н.И., и др. Роль микроРНК как регуляторов системной воспалительной реакции при метаболическом синдроме, вызванном противосудорожными препаратами. Эпилепсия и пароксизмальные состояния. 2025;17(2):208-226. https://doi.org/10.17749/2077-8333/epi.par.con.2025.239 [Shnayder NA, Pekarets NA, Pekarets NI, et al. The role of microRNAs as regulators of systemic inflammatory response in anticonvulsant-induced metabolic syndrome. Epilepsy paroxysmal cond. 2025;17(2):208-26. doi:10.17749/2077-8333/epi.par.con.2025.239 (In Russ.)]Шнайдер Н.А., Пекарец Н.А., Пекарец Н.И., и др. Роль микроРНК как регуляторов системной воспалительной реакции при метаболическом синдроме, вызванном противосудорожными препаратами. Эпилепсия и пароксизмальные состояния. 2025;17(2):208-226. https://doi.org/10.17749/2077-8333/epi.par.con.2025.239 [Shnayder NA, Pekarets NA, Pekarets NI, et al. The role of microRNAs as regulators of systemic inflammatory response in anticonvulsant-induced metabolic syndrome. Epilepsy paroxysmal cond. 2025;17(2):208-26. doi:10.17749/2077-8333/epi.par.con.2025.239 (In Russ.)]Насырова P.Ф., Сивакова Н.А., Липатова Л.В., и др. Биологические маркеры эффективности и безопасности противоэпилептических препаратов: фармакогенетика и фармакокинетика. Сибирское медицинское обозрение. 2017;(1):17-25. doi: 10.20333/2500136-2017-1-17-25 [Nasyrova RF, Sivakova NA, Lipatova LV, et al. Biological Markers of the Antiepileptic Drugs Efficacy and Safety: Pharmacogenetics and Pharmacokinetics. Siberian Med Rev. 2017;(1):17-25. (In Russ.)]Насырова P.Ф., Сивакова Н.А., Липатова Л.В., и др. Биологические маркеры эффективности и безопасности противоэпилептических препаратов: фармакогенетика и фармакокинетика. Сибирское медицинское обозрение. 2017;(1):17-25. doi: 10.20333/2500136-2017-1-17-25 [Nasyrova RF, Sivakova NA, Lipatova LV, et al. Biological Markers of the Antiepileptic Drugs Efficacy and Safety: Pharmacogenetics and Pharmacokinetics. Siberian Med Rev. 2017;(1):17-25. (In Russ.)]García-Giménez JL, Seco-Cervera M, Tollefsbol TO, et al. Epigenetic biomarkers: Current strategies and future challenges for their use in the clinical laboratory. Crit Rev Clin Lab Sci. 2017;54(7-8):529-50. doi:10.1080/10408363.2017.1410520García-Giménez JL, Seco-Cervera M, Tollefsbol TO, et al. Epigenetic biomarkers: Current strategies and future challenges for their use in the clinical laboratory. Crit Rev Clin Lab Sci. 2017;54(7-8):529-50. doi:10.1080/10408363.2017.1410520Xicota L, De toma I, Maffioletti E, et al. Recommendations for pharmacotranscriptomic profiling of drug response in CNS disorders. Eur Neuropsychopharmacol. 2022;54:41-53. doi:10.1016/j.euroneuro.2021.10.005Xicota L, De toma I, Maffioletti E, et al. Recommendations for pharmacotranscriptomic profiling of drug response in CNS disorders. Eur Neuropsychopharmacol. 2022;54:41-53. doi:10.1016/j.euroneuro.2021.10.005Шнайдер Н.А., Гречкина В.В., Архипов В.В., Насырова Р.Ф. Фармакогенетически-информированная фармакометаболомика как инновационный подход к оценке безопасности и риска фармакотерапии препаратами вальпроевой кислоты. Безопасность и риск фармакотерапии. 2023;11(4):450-462. doi: 10.30895/2312-7821-2023-386 [Shnayder NA, Grechkina VV, Arkhipov VV, Nasyrova RF. Pharmacogenetics Informed Pharmacometabolomics as an Innovative Approach to Assessing the Safety and Risk of Pharmacotherapy with Valproic Acid. Saf Risk Pharmacother. 2023;11(4):450-62.]Шнайдер Н.А., Гречкина В.В., Архипов В.В., Насырова Р.Ф. Фармакогенетически-информированная фармакометаболомика как инновационный подход к оценке безопасности и риска фармакотерапии препаратами вальпроевой кислоты. Безопасность и риск фармакотерапии. 2023;11(4):450-462. doi: 10.30895/2312-7821-2023-386 [Shnayder NA, Grechkina VV, Arkhipov VV, Nasyrova RF. Pharmacogenetics Informed Pharmacometabolomics as an Innovative Approach to Assessing the Safety and Risk of Pharmacotherapy with Valproic Acid. Saf Risk Pharmacother. 2023;11(4):450-62.]Якимов А.М., Тимечко Е.Е., Парамонова А.И., и др. Гипотезы развития и стратегии преодоления лекарственной устойчивости при эпилепсии. Часть I: Гипотезы развития. Эпилепсия и пароксизмальные состояния. 2024;16(4):375-384. Doi: 10.17749/2077-8333/epi.par.con.2024.210 [Yakimov AM, Timechko EE, Paramonova AI, et al. Hypotheses of development and strategies for overcoming drug resistance in epilepsy. Part I: Hypotheses of development. Epilepsy paroxysmal cond. 2025;16(4):375-84. (In Russ.)].Якимов А.М., Тимечко Е.Е., Парамонова А.И., и др. Гипотезы развития и стратегии преодоления лекарственной устойчивости при эпилепсии. Часть I: Гипотезы развития. Эпилепсия и пароксизмальные состояния. 2024;16(4):375-384. Doi: 10.17749/2077-8333/epi.par.con.2024.210 [Yakimov AM, Timechko EE, Paramonova AI, et al. Hypotheses of development and strategies for overcoming drug resistance in epilepsy. Part I: Hypotheses of development. Epilepsy paroxysmal cond. 2025;16(4):375-84. (In Russ.)].Stafstrom CE. Mechanisms of action of antiepileptic drugs: the search for synergy. Curr Opin Neurol. 2010;23(2):157-63. doi:10.1097/WCO.0b013e32833735b5Stafstrom CE. Mechanisms of action of antiepileptic drugs: the search for synergy. Curr Opin Neurol. 2010;23(2):157-63. doi:10.1097/WCO.0b013e32833735b5Kong F, Ma C, Zhong M. Epigenetic Effects Mediated by Antiepileptic Drugs and their Potential Application. Curr Neuropharmacol. 2020;18(2):153-66. doi:10.2174/1570159X17666191010094849Kong F, Ma C, Zhong M. Epigenetic Effects Mediated by Antiepileptic Drugs and their Potential Application. Curr Neuropharmacol. 2020;18(2):153-66. doi:10.2174/1570159X17666191010094849Devonshire AS, Whale AS, Gutteridge A, et al. Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem. 2014;406(26): 6499-6512. doi:10.1007/s00216-014-7835-3Devonshire AS, Whale AS, Gutteridge A, et al. Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem. 2014;406(26): 6499-6512. doi:10.1007/s00216-014-7835-3Fan J, Krautkramer KA, Feldman JL, Denu JM. Metabolic Regulation of Histone Post-Translational Modifications. ACS Chem Biol. 2015;10(1):95 108. doi:10.1021/cb500846uFan J, Krautkramer KA, Feldman JL, Denu JM. Metabolic Regulation of Histone Post-Translational Modifications. ACS Chem Biol. 2015;10(1):95 108. doi:10.1021/cb500846uGottlicher M. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo J. 2001;20(24):6969-78. doi:10.1093/emboj/20.24.6969Gottlicher M. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo J. 2001;20(24):6969-78. doi:10.1093/emboj/20.24.6969Shnayder NA, Grechkina VV, Khasanova AK, et al. Therapeutic and Toxic Effects of Valproic Acid Metabolites. Metabolites. 2023;13(1):134. doi:10.3390/metabo13010134Shnayder NA, Grechkina VV, Khasanova AK, et al. Therapeutic and Toxic Effects of Valproic Acid Metabolites. Metabolites. 2023;13(1):134. doi:10.3390/metabo13010134Salminen JK, Tammela TL, Auvinen A, Murtola TJ. Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study. Cancer Causes Control. 2016;27(5): 637-45. doi:10.1007/s10552-016-0737-2Salminen JK, Tammela TL, Auvinen A, Murtola TJ. Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study. Cancer Causes Control. 2016;27(5): 637-45. doi:10.1007/s10552-016-0737-2Salminen JK, Tammela TL, Auvinen A, Murtola TJ. Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study. Cancer Causes Control. 2016;27(5): 637-45. doi:10.1007/s10552-016-0737-219.Salminen JK, Tammela TL, Auvinen A, Murtola TJ. Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study. Cancer Causes Control. 2016;27(5): 637-45. doi:10.1007/s10552-016-0737-219.Stettner M, Krämer G, Strauss A, et al. Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer. Eur J Cancer Prev. 2012;21(1):55-64. doi:10.1097/cej.0b013e32834a7e6fStettner M, Krämer G, Strauss A, et al. Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer. Eur J Cancer Prev. 2012;21(1):55-64. doi:10.1097/cej.0b013e32834a7e6fWalker HK, Hall WD, Hurst JW. Epstein CM. Epilepsy. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Boston: Butterworths. 1990. https://www.ncbi.nlm.nih.gov/books/NBK379/Walker HK, Hall WD, Hurst JW. Epstein CM. Epilepsy. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Boston: Butterworths. 1990. https://www.ncbi.nlm.nih.gov/books/NBK379/Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010;50(4):298-301. doi:10.1016/j.ymeth.2010.01.032Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010;50(4):298-301. doi:10.1016/j.ymeth.2010.01.032Hara Y, Ago Y, Takano E, et al. Prenatal exposure to valproic acid increases miR-132 levels in the mouse embryonic brain. Mol Autism. 2017;8(1):33. doi:10.1186/s13229-017-0149-5Hara Y, Ago Y, Takano E, et al. Prenatal exposure to valproic acid increases miR-132 levels in the mouse embryonic brain. Mol Autism. 2017;8(1):33. doi:10.1186/s13229-017-0149-5Pouché L, Vitobello A, Römer M, et al. Xenobiotic CAR Activators Induce Dlk1-Dio3 Locus Noncoding RNA Expression in Mouse Liver. Toxicol Sci. 2017;158(2):367-78. doi:10.1093/toxsci/kfx104Pouché L, Vitobello A, Römer M, et al. Xenobiotic CAR Activators Induce Dlk1-Dio3 Locus Noncoding RNA Expression in Mouse Liver. Toxicol Sci. 2017;158(2):367-78. doi:10.1093/toxsci/kfx104Monroy-Arreola A, Durán-Figueroa NV, Méndez-Flores S, et al. Up-Regulation of T-Cell Activation MicroRNAs in Drug-Specific CD4+ T-Cells from Hypersensitive Patients. Chem Res Toxicol. 2018;31(6):454-61. doi:10.1021/acs.chemrestox.7b00330Monroy-Arreola A, Durán-Figueroa NV, Méndez-Flores S, et al. Up-Regulation of T-Cell Activation MicroRNAs in Drug-Specific CD4+ T-Cells from Hypersensitive Patients. Chem Res Toxicol. 2018;31(6):454-61. doi:10.1021/acs.chemrestox.7b00330Timechko EE, Lysova KD, Yakimov AM, et al. Circulating microRNAs as Biomarkers of Various Forms of Epilepsy. Med Sci. 2025;13(1):7. doi:10.3390/medsci13010007Timechko EE, Lysova KD, Yakimov AM, et al. Circulating microRNAs as Biomarkers of Various Forms of Epilepsy. Med Sci. 2025;13(1):7. doi:10.3390/medsci13010007Yakovleva KD, Dmitrenko DV, Panina IS, et al. Expression Profile of miRs in Mesial Temporal Lobe Epilepsy: Systematic Review. Int J Mol Sci. 2022;23(2):951. doi:10.3390/ijms23020951Yakovleva KD, Dmitrenko DV, Panina IS, et al. Expression Profile of miRs in Mesial Temporal Lobe Epilepsy: Systematic Review. Int J Mol Sci. 2022;23(2):951. doi:10.3390/ijms23020951Panina YS, Timechko EE, Usoltseva AA, et al. Biomarkers of Drug Resistance in Temporal Lobe Epilepsy in Adults. Metabolites. 2023;13(1):83. doi:10.3390/metabo13010083Panina YS, Timechko EE, Usoltseva AA, et al. Biomarkers of Drug Resistance in Temporal Lobe Epilepsy in Adults. Metabolites. 2023;13(1):83. doi:10.3390/metabo13010083Сычев Д.А. Генетические особенности пациента могут влиять на профиль эффективности и безопасности лекарственного препарата. Безопасность и риск фармакотерапии. 2024;12(2):127-131. Doi: 10.30895/2312-7821-2024-12-2-127-131 [Sychev DA. Genetic features of a patient may influence the efficacy and safety profile of a medicinal product. Safety and Risk of Pharmacotherapy. 2024;12(2):127-131. (In Russ.)]Сычев Д.А. Генетические особенности пациента могут влиять на профиль эффективности и безопасности лекарственного препарата. Безопасность и риск фармакотерапии. 2024;12(2):127-131. Doi: 10.30895/2312-7821-2024-12-2-127-131 [Sychev DA. Genetic features of a patient may influence the efficacy and safety profile of a medicinal product. Safety and Risk of Pharmacotherapy. 2024;12(2):127-131. (In Russ.)]Bochanova EA, Gusev SD. The Frequency and Structure of Adverse Drug Reactions in the Pharmacotherapy of Epilepsy. Pers Psychiatry Neurol. 2024;4(1):18-25. doi:10.52667/10.52667/2712-9179-2024-4-1-18-25Bochanova EA, Gusev SD. The Frequency and Structure of Adverse Drug Reactions in the Pharmacotherapy of Epilepsy. Pers Psychiatry Neurol. 2024;4(1):18-25. doi:10.52667/10.52667/2712-9179-2024-4-1-18-25Van breda SG, Claessen SM, Van herwijnen M, et al. Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018;393:160-70. doi:10.1016/j.tox.2017.11.013Van breda SG, Claessen SM, Van herwijnen M, et al. Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018;393:160-70. doi:10.1016/j.tox.2017.11.013Ni G, Qin J, Chen Z, et al. Associations between genetic variation in one-carbon metabolism and leukocyte DNA methylation in valproate-treated patients with epilepsy. Clin Nutr. 2018;37(1):308-12. doi:10.1016/j.clnu.2017.01.004Ni G, Qin J, Chen Z, et al. Associations between genetic variation in one-carbon metabolism and leukocyte DNA methylation in valproate-treated patients with epilepsy. Clin Nutr. 2018;37(1):308-12. doi:10.1016/j.clnu.2017.01.004Hirsch MM, Deckmann I, Fontes-Dutra M, et al. Behavioral alterations in autism model induced by valproic acid and translational analysis of circulating microRNA. Food Chem Toxicol. 2018;115:336-43. doi:10.1016/j.fct.2018.02.061Hirsch MM, Deckmann I, Fontes-Dutra M, et al. Behavioral alterations in autism model induced by valproic acid and translational analysis of circulating microRNA. Food Chem Toxicol. 2018;115:336-43. doi:10.1016/j.fct.2018.02.061Sakakibara Y, Katoh M, Kondo Y, Nadai M. Effects of Phenobarbital on Expression of UDP-Glucuronosyltransferase 1a6 and 1a7 in Rat Brain. Drug Metab Dispos. 2016;44(3):370-7. doi:10.1124/dmd.115.067439Sakakibara Y, Katoh M, Kondo Y, Nadai M. Effects of Phenobarbital on Expression of UDP-Glucuronosyltransferase 1a6 and 1a7 in Rat Brain. Drug Metab Dispos. 2016;44(3):370-7. doi:10.1124/dmd.115.067439Miousse IR, Murphy LA, Lin H, et al. Dose-response analysis of epigenetic, metabolic, and apical endpoints after short-term exposure to experimental hepatotoxicants. Food Chem Toxicol. 2017;109:690-702. doi:10.1016/j.fct.2017.05.013Miousse IR, Murphy LA, Lin H, et al. Dose-response analysis of epigenetic, metabolic, and apical endpoints after short-term exposure to experimental hepatotoxicants. Food Chem Toxicol. 2017;109:690-702. doi:10.1016/j.fct.2017.05.013Ookubo M, Kanai H, Aoki H, Yamada N. Antidepressants and mood stabilizers effects on histone deacetylase expression in C57BL/6 mice: Brain region specific changes. J Psychiatr Res. 2013;47(9):1204-14. doi:10.1016/j.jpsychires.2013.05.028Ookubo M, Kanai H, Aoki H, Yamada N. Antidepressants and mood stabilizers effects on histone deacetylase expression in C57BL/6 mice: Brain region specific changes. J Psychiatr Res. 2013;47(9):1204-14. doi:10.1016/j.jpsychires.2013.05.028Al-Ansari A, Robertson NP. Anti-epileptics and pregnancy: an update. J Neurol. 2018;265(11):2749-51. doi:10.1007/s00415-018-9058-6Al-Ansari A, Robertson NP. Anti-epileptics and pregnancy: an update. J Neurol. 2018;265(11):2749-51. doi:10.1007/s00415-018-9058-6Pavlovic S, Kotur N, Stankovic B, et al. Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment. Genes. 2019;10(3):191. doi:10.3390/genes10030191Pavlovic S, Kotur N, Stankovic B, et al. Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment. Genes. 2019;10(3):191. doi:10.3390/genes10030191Dini A, Barker H, Piki E, et al. A multiplex single-cell RNA-Seq pharmacotranscriptomics pipeline for drug discovery. Nat Chem Biol. 2025;21(3):432-42. doi:10.1038/s41589-024-01761-8Dini A, Barker H, Piki E, et al. A multiplex single-cell RNA-Seq pharmacotranscriptomics pipeline for drug discovery. Nat Chem Biol. 2025;21(3):432-42. doi:10.1038/s41589-024-01761-8Tan N, Tang H, Lin G, et al. Epigenetic Downregulation of Scn3a Expression by Valproate: a Possible Role in Its Anticonvulsant Activity. Mol Neurobiol. 2017;54(4):2831-42. doi:10.1007/s12035-016-9871-9Tan N, Tang H, Lin G, et al. Epigenetic Downregulation of Scn3a Expression by Valproate: a Possible Role in Its Anticonvulsant Activity. Mol Neurobiol. 2017;54(4):2831-42. doi:10.1007/s12035-016-9871-9Dezsi G, Ozturk E, Stanic D, Powell KL, Blumenfeld H, O'Brien TJ, Jones NC. Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy. Epilepsia. 2013;54(4):635-43. doi:10.1111/epi.12118Dezsi G, Ozturk E, Stanic D, Powell KL, Blumenfeld H, O'Brien TJ, Jones NC. Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy. Epilepsia. 2013;54(4):635-43. doi:10.1111/epi.12118Vukićević V, Qin N, Balyura M, et al. Valproic acid enhances neuronal differentiation of sympathoadrenal progenitor cells. Mol Psychiatry. 2015;20(8):941-50. doi:10.1038/mp.2015.3Vukićević V, Qin N, Balyura M, et al. Valproic acid enhances neuronal differentiation of sympathoadrenal progenitor cells. Mol Psychiatry. 2015;20(8):941-50. doi:10.1038/mp.2015.3Zhang C, Zhang E, Yang L, et al. Histone deacetylase inhibitor treated cell sheet from mouse tendon stem/progenitor cells promotes tendon repair. Biomaterials. 2018;172:66-82. doi:10.1016/j.biomaterials.2018.03.043Zhang C, Zhang E, Yang L, et al. Histone deacetylase inhibitor treated cell sheet from mouse tendon stem/progenitor cells promotes tendon repair. Biomaterials. 2018;172:66-82. doi:10.1016/j.biomaterials.2018.03.043Oikawa H, Goh WW, Lim VK, et al. Valproic acid mediates miR-124 to down-regulate a novel protein target, GNAI1. Neurochem Int. 2015;91: 62-71. doi:10.1016/j.neuint.2015.10.010Oikawa H, Goh WW, Lim VK, et al. Valproic acid mediates miR-124 to down-regulate a novel protein target, GNAI1. Neurochem Int. 2015;91: 62-71. doi:10.1016/j.neuint.2015.10.010Lin T, Ren Q, Zuo W, et al. Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs. J Exp Clin Cancer Res. 2019;38(1):150. doi:10.1186/s13046-019-1160-9Lin T, Ren Q, Zuo W, et al. Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs. J Exp Clin Cancer Res. 2019;38(1):150. doi:10.1186/s13046-019-1160-9Bellissimo T, Ganci F, Gallo E, et al. Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation. Mol Cancer. 2017;16(1):88. doi:10.1186/s12943-017-0655-2Bellissimo T, Ganci F, Gallo E, et al. Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation. Mol Cancer. 2017;16(1):88. doi:10.1186/s12943-017-0655-2Houtepen LC, Van bergen AH, Vinkers CH, Boks MP. DNA Methylation Signatures of Mood Stabilizers and Antipsychotics in Bipolar Disorder. Epigenomics. 2016;8(2):197-208. doi:10.2217/epi.15.98Houtepen LC, Van bergen AH, Vinkers CH, Boks MP. DNA Methylation Signatures of Mood Stabilizers and Antipsychotics in Bipolar Disorder. Epigenomics. 2016;8(2):197-208. doi:10.2217/epi.15.98Scicchitano BM, Sorrentino S, Proietti G, Lama G, Dobrowolny G, Catizone A, Binda E, Larocca LM, Sica Get al. Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Cancer Cell Int. 2018;18(1):136. doi:10.1186/s12935-018-0626-8Scicchitano BM, Sorrentino S, Proietti G, Lama G, Dobrowolny G, Catizone A, Binda E, Larocca LM, Sica Get al. Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Cancer Cell Int. 2018;18(1):136. doi:10.1186/s12935-018-0626-8Dyrvig M, Qvist P, Lichota J, et al. DNA Methylation Analysis of BRD1 Promoter Regions and the Schizophrenia rs138880 Risk Allele. Plos One. 2017;12(1):e0170121. doi:10.1371/journal.pone.0170121Dyrvig M, Qvist P, Lichota J, et al. DNA Methylation Analysis of BRD1 Promoter Regions and the Schizophrenia rs138880 Risk Allele. Plos One. 2017;12(1):e0170121. doi:10.1371/journal.pone.0170121Bang SR, Ambavade SD, Jagdale PG, et al. Lacosamide reduces HDAC levels in the brain and improves memory: Potential for treatment of Alzheimer's disease. Pharmacol Biochem Behav. 2015;134:65-9. doi:10.1016/j.pbb.2015.04.011Bang SR, Ambavade SD, Jagdale PG, et al. Lacosamide reduces HDAC levels in the brain and improves memory: Potential for treatment of Alzheimer's disease. Pharmacol Biochem Behav. 2015;134:65-9. doi:10.1016/j.pbb.2015.04.011Rizzo A, Donzelli S, Girgenti V, et al. In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells. J Exp Clin Cancer Res. 2017;36(1):76. doi:10.1186/s13046-017-0546-9Rizzo A, Donzelli S, Girgenti V, et al. In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells. J Exp Clin Cancer Res. 2017;36(1):76. doi:10.1186/s13046-017-0546-9Zong L, Zhou L, Hou Y, et al. Genetic and epigenetic regulation on the transcription of GABRB2 : Genotype-dependent hydroxymethylation and methylation alterations in schizophrenia. J Psychiatr Res. 2017;88:9-17. doi:10.1016/j.jpsychires.2016.12.019Zong L, Zhou L, Hou Y, et al. Genetic and epigenetic regulation on the transcription of GABRB2 : Genotype-dependent hydroxymethylation and methylation alterations in schizophrenia. J Psychiatr Res. 2017;88:9-17. doi:10.1016/j.jpsychires.2016.12.019Stark T, Ruda-Kucerova J, Iannotti FA, et al. Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. Neuropharmacology. 2019;146:212-21. doi:10.1016/j.neuropharm.2018.11.035Stark T, Ruda-Kucerova J, Iannotti FA, et al. Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. Neuropharmacology. 2019;146:212-21. doi:10.1016/j.neuropharm.2018.11.035Da silva VK, De freitas BS, Dornelles VC, et al. Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: Reversal by cannabidiol. Brain Res Bull. 2018;139:1-8. doi:10.1016/j.brainresbull.2018.01.014Da silva VK, De freitas BS, Dornelles VC, et al. Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: Reversal by cannabidiol. Brain Res Bull. 2018;139:1-8. doi:10.1016/j.brainresbull.2018.01.014Verbist B, Klambauer G, Vervoort L, et al. Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project. Drug Discov Today. 2015;20(5):505-13. doi:10.1016/j.drudis.2014.12.014Verbist B, Klambauer G, Vervoort L, et al. Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project. Drug Discov Today. 2015;20(5):505-13. doi:10.1016/j.drudis.2014.12.014Garcia-Rosa S, De freitas brenha B, Da rocha VF, et al. Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies. Curr Neuropharmacol. 2021;19(6):813-31. doi:10.2174/1570159X18666200915151909Garcia-Rosa S, De freitas brenha B, Da rocha VF, et al. Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies. Curr Neuropharmacol. 2021;19(6):813-31. doi:10.2174/1570159X18666200915151909Jaitin DA, Weiner A, Yofe I, et al. Dissecting Immune Circuits by Linking CRISPR-Pooled Screens with Single-Cell RNA-Seq. Cell. 2016;167(7):1883-1896.e15. doi:10.1016/j.cell.2016.11.039Jaitin DA, Weiner A, Yofe I, et al. Dissecting Immune Circuits by Linking CRISPR-Pooled Screens with Single-Cell RNA-Seq. Cell. 2016;167(7):1883-1896.e15. doi:10.1016/j.cell.2016.11.039Kurata M, Yamamoto K, Moriarity BS, et al. CRISPR/Cas9 library screening for drug target discovery. J Hum Genet. 2018;63(2):179-86. doi:10.1038/s10038-017-0376-9Kurata M, Yamamoto K, Moriarity BS, et al. CRISPR/Cas9 library screening for drug target discovery. J Hum Genet. 2018;63(2):179-86. doi:10.1038/s10038-017-0376-9Lin W, He M, Fan YN, Baines RA. An RNAi-mediated screen identifies novel targets for next-generation antiepileptic drugs based on increased expression of the homeostatic regulator pumilio. J Neurogenetics. 2018;32(2):106-17. doi:10.1080/01677063.2018.1465570Lin W, He M, Fan YN, Baines RA. An RNAi-mediated screen identifies novel targets for next-generation antiepileptic drugs based on increased expression of the homeostatic regulator pumilio. J Neurogenetics. 2018;32(2):106-17. doi:10.1080/01677063.2018.1465570Wang L, Song L, Chen X, et al. microRNA-139-5p confers sensitivity to antiepileptic drugs in refractory epilepsy by inhibition of MRP1. Cns Neurosci Ther. 2020;26(4):465-74. doi:10.1111/cns.13268Wang L, Song L, Chen X, et al. microRNA-139-5p confers sensitivity to antiepileptic drugs in refractory epilepsy by inhibition of MRP1. Cns Neurosci Ther. 2020;26(4):465-74. doi:10.1111/cns.13268Huang Y, Jiang J, Zheng G, et al. miR-139-5p modulates cortical neuronal migration by targeting Lis1 in a rat model of focal cortical dysplasia. Int J Mol Med. 2014;33(6):1407-14. doi:10.3892/ijmm.2014.1703Huang Y, Jiang J, Zheng G, et al. miR-139-5p modulates cortical neuronal migration by targeting Lis1 in a rat model of focal cortical dysplasia. Int J Mol Med. 2014;33(6):1407-14. doi:10.3892/ijmm.2014.1703

The authors declare that there are no conflicts of interest present.